Robert Lafyatis mostly deals with Immunology, Pathology, Transforming growth factor, Gene expression and Fibrosis. He interconnects Scleroderma and Disease in the investigation of issues within Immunology. The Pathology study combines topics in areas such as Interstitial lung disease, Growth factor and Arthritis.
He focuses mostly in the field of Transforming growth factor, narrowing it down to topics relating to Signal transduction and, in certain cases, Homeostasis. The concepts of his Gene expression study are interwoven with issues in Molecular biology, Regulation of gene expression and Interferon. His Fibrosis research is multidisciplinary, relying on both Acquired immune system, Fibroblast and Immunity.
His main research concerns Immunology, Fibrosis, Pathology, Cancer research and Scleroderma. Immunology is a component of his Immune system, Pathogenesis, Innate immune system, Inflammation and Cytokine studies. His Pathogenesis research is multidisciplinary, incorporating perspectives in Gene expression and Disease.
Robert Lafyatis has included themes like Fibroblast and Transforming growth factor, Extracellular matrix, Cell biology in his Fibrosis study. His Pathology research includes themes of Lung and Interstitial lung disease. His Scleroderma study introduces a deeper knowledge of Internal medicine.
His primary areas of study are Cancer research, Internal medicine, Lung, Fibrosis and Cell. His studies deal with areas such as Toll-Interacting Protein and Pathogenesis as well as Lung. The study incorporates disciplines such as Fibroblast, Extracellular matrix, Cell biology and Growth factor in addition to Fibrosis.
His research in Cell intersects with topics in RNA, Gene and Molecular biology. In his research, Microarray is intimately related to Pathology, which falls under the overarching field of Idiopathic pulmonary fibrosis. His Immune system study improves the overall literature in Immunology.
The scientist’s investigation covers issues in Cancer research, Immune system, Fibrosis, T cell and Tumor microenvironment. His studies in Cancer research integrate themes in fields like Blockade, Extracellular matrix and Cell type. Immune system is the subject of his research, which falls under Immunology.
His Fibrosis research incorporates elements of Growth factor, Platelet-derived growth factor receptor, Skin biopsy, Disease and Fibroblast. Robert Lafyatis combines subjects such as Oncology, Transforming growth factor, GDF15 and CTGF with his study of Disease. Robert Lafyatis usually deals with Tumor microenvironment and limits it to topics linked to Cancer immunotherapy and Memory T cell, Receptor expression, Cell biology, Adoptive cell transfer and Interleukin 10.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex.
Seong Jin Kim;Peter Angel;Robert Lafyatis;Kazue Hattori.
Molecular and Cellular Biology (1990)
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Gerald S. Horan;Susan Wood;Victor Ona;Dan Jun Li.
American Journal of Respiratory and Critical Care Medicine (2008)
Generation of Transgene‐Free Lung Disease‐Specific Human Induced Pluripotent Stem Cells Using a Single Excisable Lentiviral Stem Cell Cassette
Aba Somers;Jyh‐Chang Jean;Cesar A. Sommer;Amel Omari.
Stem Cells (2010)
Localization and actions of transforming growth factor-beta s in the embryonic nervous system.
K.C. Flanders;G. Ludecke;S. Engels;D.S. Cissel.
Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids.
R Lafyatis;E F Remmers;A B Roberts;D E Yocum.
Journal of Clinical Investigation (1989)
Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system
K. Unsicker;K.C. Flanders;D.S. Cissel;R. Lafyatis.
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna;Christopher P Denton;Angelika Jahreis;Jacob M van Laar.
The Lancet (2016)
A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
Michael R. York;Taro Nagai;Alyson J. Mangini;Raphaël Lemaire.
Arthritis & Rheumatism (2007)
Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis
L. Van Bon;L. Van Bon;A. J. Affandi;A. J. Affandi;J. Broen;J. Broen;R. B. Christmann.
The New England Journal of Medicine (2014)
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
Robert Lafyatis;Eugene Kissin;Michael York;Giuseppina Farina.
Arthritis & Rheumatism (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: